Researchers have created a personal epidemic.

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Researchers have created a personal epidemic.

Latest News

WHO Flags Growing Health Workforce Gap as Workers and Patients Age

Doctors Are Leaning Into Anti-Hustle Vacations

The Market Forces Quietly Adding Thousands to Patient Bills

FDA Clears First Standalone Robotic Blood Draw System

Med Students’ Secret Weapon? Sleep

Oncology Firm Novocure Says Cyberattack Exposed US Patient Records

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

Where Have All the Leaders Gone? PAs Want to Step Up

CMS Proposes Major Medicare Physician Payment Overhaul to Boost Primary Care

Married to Medicine: The Other Side of the Story

Cigna Invests $100 Million in New AI-powered Specialty Pharmacy Program

Resident Doctors in England Vote for UK Government's Pay Offer, Ending Strikes

Democratic-led States Sue Over Trump Administration's Medicaid Work Requirement Rule

Trump Cuts New York Funding for Medicaid Fraud Unit

Europe Must Rethink Medicine Pricing or Risk Losing Investment

Medicare AI Creates Errors and Delays for Patients, Doctors

Analysis-Big Pharma Taps UK Playbook to Pressure European Capitals on Drug Prices

Studies Confirm Private Equity Dangers

Cholera Outbreak in Nigeria's Borno Kills 74, Infects Thousands Since May

Nurses Filling Doctor Gaps: What Happens to Hard Cases?

FDA Grants Emergency Approval for Over-the-counter Drug to Treat Screwworm in Pets

More Nurses are Clocking in to Second Jobs

Sandoz Files European Complaint About Chinese Antibiotic Imports

Recommended News For You

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

Novel Psychedelic Promising on Resistant Depression

Climate change is expected to increase the number of suicide deaths

Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.

Palliative Care Remains Uncommon in Young Adults With Cancer

Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer

Brain MRI Surveillance Alone May Be Enough in SCLC

Recommended Articles For You

Engineered Niches for Blood-Cell Regeneration: Current Concepts and Clinical Implications

Megakaryocyte Immune Cell Crosstalk: Mechanisms, Clinical Insights, and Therapeutic Implications

Spatial Transcriptomics in Oncology: Transforming Tumor Biology and Precision Medicine

Understanding Sepsis and Precision-Medicine-Based Immunotherapy: A Pathophysiological Perspective

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.